Pich A, Margaria E, Chiusa L, Ponti R, Geuna M
Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin, Italy.
Hum Pathol. 1996 Jul;27(7):676-82. doi: 10.1016/s0046-8177(96)90397-4.
DNA flow cytometry and the monoclonal antibody DO7 were applied in formalin-fixed, paraffin-embedded specimens from 34 primary male breast carcinomas to verify whether DNA ploidy and p53 expression were associated with survival and proliferative activity. They were compared with tumor clinicopathologic features, sex steroid hormone receptors and cell proliferative activity, assessed by the counts of the argyrophilic nucleolar organizer regions (AgNORs), the monoclonal antibody PC10 against the proliferating cell nuclear antigen and the monoclonal antibody MIB-1. A significant correlation was found between survival and tumor ploidy (median survival, 77 months for diploid but only 38 months for aneuploid cases; P = .03) and p53 expression (median survival, 95 months for cases with p53 scores < or = 14.06% versus 33 for cases with P53 scores > 14.06%; P = .0004; median survival, 99 months for p53 negative vs 39 for positive cases; P = .007). Tumor histological grade (P = .006), AgNOR counts (P = .0001), PC10 scores (P = .002), and MIB-1 scores (P = .001) were also associated with prognosis. In the multivariate analysis, only p53 scores (P = .001) or p53 immunopositivity (P = .003) and AgNOR counts (P = .022) retained an independent prognostic significance. Aneuploid tumors had higher AgNOR counts (P = .002), PC10 (P = .007), MIB-1 (P = .006), and p53 scores (P = .01) than diploid cases. A linear relationship was observed between p53 scores and AgNOR counts (r = .41; P = .014), PC10 (r = .46; P = .005), and MIB-1 scores (r = .44; P = .011). These results indicate that DNA ploidy and p53 expression are associated with survival and cell proliferative activity in male breast carcinoma. Quantitative parameters, such as DNA ploidy, p53 scores, AgNOR counts, PC10, and MIB-1 scores substantially improve the prognostic significance of the traditional parameters in male breast carcinoma.
采用DNA流式细胞术和单克隆抗体DO7对34例原发性男性乳腺癌福尔马林固定、石蜡包埋标本进行检测，以验证DNA倍体和p53表达是否与生存率及增殖活性相关。将其与肿瘤临床病理特征、性类固醇激素受体及细胞增殖活性进行比较，细胞增殖活性通过嗜银核仁组织区（AgNORs）计数、抗增殖细胞核抗原单克隆抗体PC10及单克隆抗体MIB-1进行评估。结果发现，生存率与肿瘤倍体（二倍体病例中位生存期为77个月，非整倍体病例仅为38个月；P = 0.03）及p53表达（p53评分≤14.06%的病例中位生存期为95个月，p53评分＞14.06%的病例为33个月；P = 0.0004；p53阴性病例中位生存期为99个月，阳性病例为39个月；P = 0.007）之间存在显著相关性。肿瘤组织学分级（P = 0.006）、AgNOR计数（P = 0.0001）、PC10评分（P = 0.002）及MIB-1评分（P = 0.001）也与预后相关。多因素分析显示，仅p53评分（P = 0.001）或p53免疫阳性（P = 0.003）及AgNOR计数（P = 0.022）具有独立的预后意义。非整倍体肿瘤的AgNOR计数（P = 0.002）、PC10（P = 0.007）、MIB-1（P = 0.006）及p53评分（P = 0.01）均高于二倍体病例。p53评分与AgNOR计数（r = 0.41；P = 0.014）、PC10（r = 0.46；P = 0.005）及MIB-1评分（r = 0.44；P = 0.011）之间呈线性关系。这些结果表明，DNA倍体和p53表达与男性乳腺癌的生存率及细胞增殖活性相关。DNA倍体、p53评分、AgNOR计数、PC10及MIB-1评分等定量参数显著提高了男性乳腺癌传统参数的预后意义。
